Pyrazinamide
- Generic Name
- Pyrazinamide
- Brand Names
- Rifater, Tebrazid
- Drug Type
- Small Molecule
- Chemical Formula
- C5H5N3O
- CAS Number
- 98-96-4
- Unique Ingredient Identifier
- 2KNI5N06TI
- Background
A pyrazine that is used therapeutically as an antitubercular agent.
- Indication
For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
- Associated Conditions
- Active Tuberculosis, Pulmonary Tuberculosis (TB)
- Associated Therapies
- -
Shortened Regimen for Drug-susceptible TB in Children
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 860
- Registration Number
- NCT06253715
- Locations
- 🇮🇳
Indian Council of Medical Research - National Institute for Research in Tuberculosis, Chennai, India
🇮🇳Dr. D.Y. Patil Medical College, Hospital and Research Center, Pimpri, Pune, India
🇮🇩Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-13
- Target Recruit Count
- 315
- Registration Number
- NCT06192160
- Locations
- 🇺🇬
12401, Joint Clinical Research Centre (JCRC)/Kampala CRS, Kampala, Uganda
🇲🇼30301, Blantyre CRS, Blantyre, Malawi
🇲🇼12001, Malawi CRS, Lilongwe, Malawi
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT06081361
- Locations
- 🇨🇳
The 8th Medical Center of Chinese Pla General Hospital, Beijing, China
🇨🇳Hebei Chest Hospital, Shijiazhuang, Hebei, China
🇨🇳Harbin Chest Hospital, Harbin, Heilongjiang, China
Intensified Short Course Regimen for TBM in Adults
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Indian Council of Medical Research
- Target Recruit Count
- 372
- Registration Number
- NCT05917340
- Locations
- 🇮🇳
ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India
PanACEA - STEP2C -01
- Conditions
- Interventions
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 270
- Registration Number
- NCT05807399
- Locations
- 🇲🇼
Kamuzu College of Health Sciences (formerly College of Medicine), Blantyre, Malawi
🇹🇿Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania
🇺🇬Makerere University Lung Institute Limited, Kampala, Uganda
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 288
- Registration Number
- NCT05766267
- Locations
- 🇺🇸
TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
🇺🇸TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT05556746
- Locations
- 🇭🇹
GHESKIO, Port-au-Prince, Haiti
🇿🇦University of Cape Town, Cape Town, South Africa
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 620
- Registration Number
- NCT05454345
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 212
- Registration Number
- NCT05306223
- Locations
- 🇨🇳
Beijing Chest Hospital, Beijing, China
🇨🇳The Pulmonary Hospital of Fuzhou in Fujian Province（The tuberculosis control and prevention Hospital of Fuzhou in Fujian Province）, Fuzhou, China
🇨🇳The Eighth Medical Center of PLA General Hospital, Beijing, China
Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
- Conditions
- Interventions
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Tuberculosis Research Centre, India
- Target Recruit Count
- 550
- Registration Number
- NCT05047055
- Locations
- 🇮🇳
National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.